We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CSAN:NYSECosan S.A. Analysis

Data as of 2026-06-18 - not real-time

$2.72

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Cosan (CSAN) is trading well below its 20‑day, 50‑day and 200‑day moving averages, signaling a bearish price trend, yet the RSI sits near 33, hinting at oversold conditions. The MACD line has just crossed above its signal line, generating a bullish histogram and suggesting a potential short‑term rebound, even as volume has been declining and volatility remains elevated at over 55% on a 30‑day basis. Fundamentally, the company posted robust revenue growth of 26% and solid operating margins above 30%, but a negative profit margin, a trailing EPS of –2.64 and a debt‑to‑equity ratio exceeding 100% underscore significant earnings and balance‑sheet pressure.
The latest HSBC downgrade to “Reduce” and a lowered price target of $3.2 reflect growing skepticism, especially given the high leverage and limited free cash flow. Nonetheless, the DCF‑derived fair value of roughly $11.5 implies a sizable upside, and the forward P/E of about 11 is well below the industry average of 20, positioning the stock as potentially undervalued for investors willing to tolerate the sector’s regulatory and geographic headwinds.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price below all major moving averages
  • RSI indicating oversold conditions
  • Recent HSBC downgrade and reduced target price

Medium Term

1–3 years
Positive
Model confidence: 6/10

Key Factors

  • Strong revenue growth and operating margins
  • DCF upside potential exceeding 50%
  • Bullish MACD crossover suggesting momentum shift

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Exposure to Brazil's energy transition and logistics infrastructure
  • High leverage and negative net earnings
  • Absence of dividend and volatile commodity pricing

Key Metrics & Analysis

Financial Health

Revenue Growth26.50%
Profit Margin-23.92%
P/E Ratio10.9
ROE-29.94%
ROA5.30%
Debt/Equity109.78
P/B Ratio3.9
Op. Cash Flow$13.8B
Free Cash Flow$511.6M
Industry P/E20.0

Technical Analysis

TrendBearish
RSI33.4
Support$2.52
Resistance$3.58
MA 20$2.90
MA 50$3.58
MA 200$4.31
MACDBullish
VolumeDecreasing
Fear & Greed Index90.95

Valuation

Fair Value$11.46
Target Price$4.11
Upside/Downside51.07%
GradeUndervalued
TypeBlend

Risk Assessment

Beta1.47
Volatility55.43%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.